<DOC>
	<DOCNO>NCT02116465</DOCNO>
	<brief_summary>The study carried-out describe compare plasma pharmacokinetics levodopa carbidopa oral single-dose administration 100 mg levodopa plus 25 mg carbidopa mean two fix combination product ( test : Isicom® 100/25 mg ; reference : Nacom® 100/25 mg ) . Additionally , describe compare safety tolerability two investigational treatment administer healthy subject .</brief_summary>
	<brief_title>Pharmacokinetic Study With Levodopa-carbidopa Fixed-dose Products Healthy Subjects After Oral Administration</brief_title>
	<detailed_description>Isicom® 100/25 mg Sinemet® ( Trade name Germany : Nacom® ) 100/25 mg authorise fixed-combination product contain 100 mg levodopa plus 25 mg carbidopa . These two formulation test bioequivalence 1997 ( DESITIN trial № LCD-010/K ) ; base regulatory provision place time ( CPMP/EWP/QWP/1401/98 ) , two formulation could accept bioequivalent . The present study propose conduct order verify confirm bioequivalence Isicom® 100/25 mg ( test formulation ) Nacom® 100/25 mg ( reference formulation ) agreement pertinent regulatory guidance come place 2010 ( CHMP Guideline On The Investigation Of Bioequivalence - CPMP/EWP/QWP/1401/98- Rev . 1/ Corr - Jan.2010 ) .</detailed_description>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Carbidopa , levodopa drug combination</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Males female ( female nonchildbearing potential childbearing potential take medically appropriate contraception ) Race : Caucasian Age : 18 45 year Body weight : 50 100 kg Body Mass Index : 18 26 kg.m2 Healthy base screen examination Willing able provide inform consent Previous participation trial participant trial last 90 day Donation blood plasma last 90 day history blood loss exceed 300 mL within last 3 month History clinically relevant allergy include hypersensitivity levodopa carbidopa related excipients Presence acute chronic infection Presence history relevant comorbidity Resting systolic blood pressure &gt; 160 &lt; 90 mmHg , diastolic blood pressure &gt; 95 &lt; 50 mmHg Clinically relevant ECGabnormalities , particular prolong QTc ( F ) &gt; 450 msec male &gt; 460 msec female Presence relevant abnormality laboratory safety test , especially low haemoglobin ( &lt; 120 g/L female ( &lt; 136 g/L male ) increase liver enzyme ( 2 time upper limit normal range ) Positive serology HBsAg anti HCV Positive HIV test Positive alcohol urine drug test screen Regular use prescription medicine ( except contraceptive ) overthecounter product , herbal product , hormone supplement , etc . 30 day prior Screening visit History alcohol and/or drug abuse and/or daily use &gt; 30 g alcohol Smoking 10 cigarettes/day equivalent tobacco product Suspicion evidence subject trustworthy reliable Suspicion evidence subject able make free consent understand information regard . Positive pregnancy test Lactating Female subject childbearing potential use appropriate contraception 3 week prior enrolment two week last dose trial medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>